December 6, 2013 / 12:01 PM / 4 years ago

UK cost agency recommends new Sanofi MS pill

LONDON, Dec 6 (Reuters) - Britain’s healthcare cost watchdog NICE has recommended that the state health service use Sanofi’s new multiple sclerosis pill Aubagio, which will be supplied at a discount.

The National Institute for Health and Clinical Excellence (NICE) - the body that decides if drugs should be paid for - said on Friday its final draft guidance recommended Aubagio, or teriflunomide, for adults with relapsing-remitting multiple sclerosis.

The drug’s list price is 13,529 pounds ($22,100) per patient a year but the size of the discount has not been disclosed.

On Thursday, NICE said it needed more information before deciding if a separate Sanofi drug for the disease - the injectable treatment Lemtrada - was worth using.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below